statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Erasca (NASDAQ:ERAS - Free Report) had its target price hoisted by The Goldman Sachs Group from $6.00 to $7.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The...

Erasca (NASDAQ:ERAS) PT Raised to $7.00

Analyst Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Erasca (ERAS Research Report) and keeping the price target at $7.00...

Erasca's Promising Naporafenib Data and Financial Stability Merit a Buy Rating

HC Wainwright restated their buy rating on shares of Erasca (NASDAQ:ERAS - Free Report) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the...

HC Wainwright Reiterates "Buy" Rating for Erasca (NASDAQ:ERAS)

Insights into Erasca Inc's Q4 and Full Year 2023 Financial and Operational PerformanceRelated Stocks: ERAS...

Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript...

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Funding from new and existing investors extends anticipated cash runway into H2 2026SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) ( Erasca ), a clinical-stage precision...

Erasca Announces $45 Million Oversubscribed Private Placement Financing

In a report released today, Naureen Quibria from Capital One Financial reiterated a Buy rating on Erasca (ERAS Research Report), with a price tar...

Erasca's Strong Clinical Data and Enhanced Financial Position Support Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC Research Report) and Erasca (ERAS...

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)

Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib...

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 1, 2018 and is headquartered in San Diego, CA.

Volume	466,397.00
52-Wk High	$3.38
52-Wk Low	$1.51

ERAS Erasca Inc

About

Feed

News

Sentiment

Earnings

Fundamentals